Guggenheim Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $98
SRPTMay 7, 2025
Read more →Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $70
SRPTMay 7, 2025
Read more →Oppenheimer Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $123
SRPTMay 7, 2025
Read more →Cantor Fitzgerald Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $81
SRPTMay 7, 2025
Read more →Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
SRPTMay 7, 2025
Read more →HC Wainwright & Co. Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $40
SRPTMay 7, 2025
Read more →Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $113
SRPTMay 7, 2025
Read more →Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $125
SRPTMay 7, 2025
Read more →Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why
SRPTSarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report.
May 6, 2025
Read more →Sarepta Therapeutics Q1 Adj. EPS $(3.42) Misses $(0.95) Estimate, Sales $744.86M Beat $683.36M Estimate
SRPTMay 6, 2025
Read more →Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $110
SRPTApril 21, 2025
Read more →HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target
SRPTApril 16, 2025
Read more →Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5
SRPTApril 15, 2025
Read more →Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $182
SRPTApril 11, 2025
Read more →Wells Fargo Initiates Coverage On Sarepta Therapeutics with Overweight Rating, Announces Price Target of $115
SRPTApril 11, 2025
Read more →HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target
SRPTApril 7, 2025
Read more →HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target
SRPTApril 4, 2025
Read more →Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
SRPTApril 3, 2025
Read more →Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $183
SRPTApril 3, 2025
Read more →HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75
SRPTApril 2, 2025
Read more →RBC Capital Downgrades Sarepta Therapeutics to Sector Perform, Lowers Price Target to $87
SRPTMarch 31, 2025
Read more →Scotiabank Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $80
SRPTMarch 20, 2025
Read more →Cantor Fitzgerald Reiterates Overweight on Sarepta Therapeutics, Maintains $163 Price Target
SRPTMarch 19, 2025
Read more →HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
SRPTMarch 19, 2025
Read more →Deutsche Bank Maintains Hold on Sarepta Therapeutics, Lowers Price Target to $99
SRPTMarch 19, 2025
Read more →12 Analysts Have This To Say About Sarepta Therapeutics
SRPTMarch 18, 2025
Read more →Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
SRPTMarch 18, 2025
Read more →Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
SRPTSarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.
March 18, 2025
Read more →Cantor Fitzgerald Reiterates Overweight on Sarepta Therapeutics, Maintains $163 Price Target
SRPTMarch 18, 2025
Read more →Sarepta Therapeutics Reports A Patient Death With Duchenne Muscular Dystrophy Following Treatment With Elevidys, Having Suffered Acute Liver Failure
SRPTMarch 18, 2025
Read more →Scotiabank Initiates Coverage On Sarepta Therapeutics with Sector Perform Rating, Announces Price Target of $105
SRPTMarch 7, 2025
Read more →Sarepta Therapeutics Files For Mixed Shelf; Size Not Disclosed
SRPTMarch 3, 2025
Read more →RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $161
SRPTFebruary 27, 2025
Read more →Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
SRPTFebruary 27, 2025
Read more →8 Analysts Have This To Say About Sarepta Therapeutics
SRPTFebruary 27, 2025
Read more →HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
SRPTFebruary 27, 2025
Read more →Sarepta Therapeutics Q4 2024 Adj. EPS $1.90, Inline, Sales $658.412M Beat $627.582M Estimate
SRPTFebruary 26, 2025
Read more →HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
SRPTFebruary 13, 2025
Read more →What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
SRPTJanuary 15, 2025
Read more →HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
SRPTJanuary 15, 2025
Read more →Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
SRPTJanuary 14, 2025
Read more →Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B
SRPTJanuary 13, 2025
Read more →A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
SRPTDecember 19, 2024
Read more →HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
SRPTDecember 19, 2024
Read more →Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.
SRPTNovember 6, 2024
Read more →12 Analysts Have This To Say About Sarepta Therapeutics
SRPTMay 20, 2024
Read more →Needham Reiterates Buy on Sarepta Therapeutics, Maintains $166 Price Target
SRPTMay 20, 2024
Read more →Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $179
SRPTMay 17, 2024
Read more →Analyst Ratings for Sarepta Therapeutics
SRPTWithin the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
September 8, 2022
Read more →A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
SRPTMorgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
September 8, 2022
Read more →